Pfizer News - May 30, 2026

Pfizer cuts prostate cancer progression risk 52%, targeting specific gene mutations

Pfizer reported Phase 3 TALAPRO-3 study results at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The trial evaluated a combination of...